Delays in regulatory approvals, especially for significant products like vaccines, can lead to investor uncertainty and short-term negative sentiment towards a company's stock. In this case, the delay is attributed to administrative constraints, not to concerns about the vaccine's efficacy or safety, which might mitigate the negative impact. However, the delay still introduces uncertainty regarding the timeline for potential revenue from the vaccine, which can lead to short-term volatility in Moderna's stock price.